Published in Cancer Weekly, July 6th, 2004
SERMs are a class of drugs that can block the cell's ability to use estrogen to stimulate the development of breast cancer. This class of anti-estrogens includes tamoxifen, which is currently used by thousands of postmenopausal women with estrogen-receptor positive cancer to prevent recurrence following completion of their chemotherapy.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.